Cardio Diagnostics Holdings, Inc. Income Taxes Disclosure

Note 10 - Income Taxes

 

Upon adoption of ASU 2023-09, Improvements to Income Tax Disclosures, as described in Note 2, Summary of Significant Accounting Policies, our loss before provision for income taxes for the year ended December 31, 2025 was as follows:

Schedule of provision for income tax
		Year Ended December 31, 2025
Domestic		$	(6,498,167	)
Foreign			—
Loss before provision for income taxes		$	(6,498,167	)

 

Loss before provision for income taxes for the year ended December 31, 2024 was $8,383,453.

 

Upon adoption of ASU 2023-09, Improvements to Income Tax Disclosures, as described in Note 2, Summary of Significant Accounting Policies, the reconciliation of taxes at the federal statutory rate to our provision for income taxes for the year ended December 31, 2025 was as follows: 

Schedule of effective income tax rate reconciliation
		Amount			Percent
Statutory U.S. federal income tax rate		$	(1,364,615	)		(21.0	)%
State income taxes, net of    federal income tax benefit			—			0.0
Tax effect of expenses that are not     deductible for income tax purposes:
Stock based compensation			20,629			0.3
Change in Valuation Allowance			1,343,986			20.7
Provision for income taxes		$	—			0.0	%

 

The reconciliation of taxes at the federal statutory rate to our provision for income taxes for the year ended December 31, 2024 in accordance with the guidance prior to the adoption of ASU 2023-09 was as follows:

		Year Ended December 31,
		2024
Statutory U.S. federal income tax rate				(21.0	)%
State income taxes, net of    federal income tax benefit				(0.0	)%
Tax effect of expenses that are not     deductible for income tax purposes:
Stock based compensation				6.3	%
Change in Valuation Allowance				14.7	%
Effective tax rate				0.0	%

 

At December 31, the significant components of the deferred tax assets (liabilities) are summarized below:

Schedule of deferred income tax assets
		2025				2024
Deferred Tax Assets:
Net operating losses		$	6,681,394			$	5,580,034
Other			2,328				2,328
Property and equipment			81,991				25,169
Total deferred tax assets			6,765,713				5,607,531
Deferred Tax Liabilities			—				—
Valuation Allowance			(6,765,713	)			(5,607,531	)
Net deferred tax assets		$	—			$	—

 

As of December 31, 2025, the Company had federal net operating loss carryforwards of approximately $23.5 million which may be carried forward indefinitely, and state net operating loss carryforwards of approximately $624,000 (Iowa) and $22.8 million (Illinois), respectively which expire at various dates from 2040 through 2045. These net operating loss carryforwards may be used to offset future taxable income and thereby reduce the Company’s U.S. federal income taxes. The net operating losses may be subject to limitation under Internal Revenue Code Section 382 should there be a greater than 50% change in ownership as determined under the regulations.

 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, management has established a full valuation allowance against all of the deferred tax assets for every period because it is more likely than not that all of the deferred tax assets will not be realized.

 

In accordance with ASC 740, a valuation allowance must be established if it is more likely than not that the deferred tax assets will not be realized. This assessment is based upon consideration of available positive and negative evidence, which includes, among other things, the Company’s most recent results of operations and expected future profitability. Based on the Company’s cumulative losses in recent years, a full valuation allowance against the Company’s deferred tax assets as of December 31, 2025 and 2024 respectively has been established as Management believes that the Company will not more likely than not realize the benefit of those deferred tax assets. Therefore, no tax provision has been recorded for the years ended December 31, 2025 and 2024, respectively.

 

The Company complies with the provisions of ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. Management has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10.

 

The Company is subject to income tax in the U.S., and certain state jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, or any states in connection with income taxes. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations.

 

The Company recognizes interest and penalties related to unrecognized tax benefits, if incurred, as a component of income tax expense. No interest or penalties have been recorded for the years ended December 31, 2025 and 2024, respectively.